Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Twice Weekly Rivastigmine Patch vs Exelon
NCT03659435Phase 1Completed
- Sponsor
- SocraTec R&D
- Start
- Aug 2018
- Primary completion
- Nov 2018
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivastigmine in Alzheimer's disease (AD), sponsored by SocraTec R&D. Started Aug 2018; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03659435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03659435.